Neuronetics, Inc.
HealthcareNASDAQ:STIM · NASDAQ Global Market
+$0.02 today
Vol 0.91M · Avg 2.43M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-174.3%
avg -71.0%
ROIC
-27.0%
avg -34.1%
ROA
-27.6%
avg -31.0%
Analysis
ROIC is currently the strongest return metric at -27.0% versus its period average of -34.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Daniel L. Reuvers | President, Chief Executive Officer & Director | $927,610.00 | — | 63 | $0.00 | <0.01% |
W. Andrew Macan | EVice President, Chief Legal Officer & Corporate Secretary | $652,545.00 | — | 53 | $897,270.00 | 1.29% |
Steven E. Pfanstiel | Executive Vice President, Treasurer & Chief Financial Officer | $557,223.00 | — | 53 | $836,643.00 | 1.20% |
Robert Greene | Senior Vice President of Sales | — | — | — | $625,017.00 | 0.90% |
Cory S. Anderson | SVP & Chief Technology Officer | — | — | — | — | — |
Francis X. Brown | Interim Principal Financial & Accounting Officer | — | — | — | $19,968.00 | 0.03% |
Jeffrey S. Jones | Senior Vice President & Chief of Operations | — | — | 70 | — | — |
Lisa Metzner-Rosas | Senior Vice President & Chief Marketing Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
12
$4.70M
Sells
14
$13.30M
Net Sentiment
$8.60M
Net selling
Most Active
Chernett Jorey
12 transactions
1–10 of 26
Analysis
Insiders reported 12 buys worth $4.70M and 14 sells worth $13.30M over the last 12 months. That adds up to net selling of $8.60M. Chernett Jorey was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +6.8% | +17.0% (10yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +6.8% over three years. Forward estimates point to Revenue at +17.0% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Genfit S.A.
GNFT
$445.68M
Prenetics Global Limited
NASDAQ:PRE
$367.72M
OraSure Technologies, Inc.
NASDAQ:OSUR
$287.79M
OmniAb, Inc.
NASDAQ:OABI
$270.34M
Perspective Therapeutics, Inc.
AMEX:CATX
$227.89M
Codexis, Inc.
NASDAQ:CDXS
$218.15M
Profound Medical Corp.
NASDAQ:PROF
$200.47M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$64.96M
Nyxoah S.A.
NASDAQ:NYXH
$55.05M
Atlantic International Corp.
NASDAQ:ATLN
$47.61M
Who manages STIM?
Neuronetics, Inc. (STIM) lists 8 active executives. The top listed executive is Steven E. Pfanstiel, Executive Vice President, Treasurer & Chief Financial Officer.
Are STIM insiders buying or selling?
Recent insider activity shows net selling of $13.73M.
Explore More
Continue the stock analysis
Jump to another research area for this company.